Physician profile
Jayeshkumar Patel
NPI 1962509265
$14,121.51
in general payments reported to CMS, 2019-2025
33 companies · $912 in 2025
The $912 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $1,026 · 2021: $3,750 · 2022: $2,111 · 2023: $2,937 · 2024: $2,966 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,417 · Travel and Lodging: $379 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,416.71 |
| Travel and Lodging | $379.17 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,634.29 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,866.71 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Novo Nordisk INC | $1,380.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,324.99 | 2021 | |
| Abbvie INC. | $1,307.91 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,045.41 | 2019-2023 | Jardiance |
| Amgen INC. | $1,039.08 | 2021-2025 | Evenity, Repatha, Repatha |
| Abbott Laboratories | $883.53 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $374.23 | 2024-2025 | Voquezna |
| Vifor Pharma, INC. | $335.53 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $316.52 | 2021-2025 | |
| Horizon Therapeutics Plc | $200.36 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.62 | 2021-2023 | Trulance, Xifaxan |
| Cardiovascular Systems INC. | $171.05 | 2020 | |
| Dexcom, INC. | $153.79 | 2021-2023 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $145.62 | 2025 | Korlym |
| Lilly USA, LLC | $127.69 | 2021-2025 | Jardiance, Emgality |
| Mannkind Corporation | $125.00 | 2023 | Afrezza |
| Otsuka America Pharmaceutical, INC. | $105.14 | 2023 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $94.77 | 2019 | |
| Nabriva Therapeutics, Plc | $51.62 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $47.88 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.68 | 2023 | Austedo |
| Pfizer INC. | $28.62 | 2023 | |
| Merck Sharp & Dohme LLC | $26.62 | 2021-2022 | |
| Angiodynamics, INC. | $23.27 | 2021 | |
| Exact Sciences Corporation | $17.41 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.41 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $17.15 | 2022 | |
| Smith+Nephew, INC. | $14.52 | 2023 | Collagenase Santyl |
| Ironwood Pharmaceuticals, INC | $14.36 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.64 | 2022 | |
| Allergan, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayeshkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.